Literature DB >> 26040771

Aberrant GSTP1 promoter methylation predicts short-term prognosis in acute-on-chronic hepatitis B liver failure.

S Gao1, F-K Sun1, Y-C Fan1,2, C-H Shi3, Z-H Zhang4, L-Y Wang1, K Wang1,2.   

Abstract

BACKGROUND: Glutathione-S-transferase P1 (GSTP1) methylation has been demonstrated to be associated with oxidative stress induced liver damage in acute-on-chronic hepatitis B liver failure (ACHBLF). AIM: To evaluate the methylation level of GSTP1 promoter in acute-on-chronic hepatitis B liver failure and determine its predictive value for prognosis.
METHODS: One hundred and five patients with acute-on-chronic hepatitis B liver failure, 86 with chronic hepatitis B (CHB) and 30 healthy controls (HC) were retrospectively enrolled. GSTP1 methylation level in peripheral mononuclear cells (PBMC) was detected by MethyLight. Clinical and laboratory parameters were obtained.
RESULTS: GSTP1 methylation levels were significantly higher in patients with acute-on-chronic hepatitis B liver failure (median 16.84%, interquartile range 1.83-59.05%) than those with CHB (median 1.25%, interquartile range 0.48-2.47%; P < 0.01) and HC (median 0.80%, interquartile range 0.67-1.27%; P < 0.01). In acute-on-chronic hepatitis B liver failure group, nonsurvivors showed significantly higher GSTP1 methylation levels (P < 0.05) than survivors. GSTP1 methylation level was significantly correlated with total bilirubin (r = 0.29, P < 0.01), prothrombin time activity (r = -0.24, P = 0.01) and model for end-stage liver disease (MELD) score (r = 0.26, P = 0.01). When used to predict 1- or 2-month mortality of acute-on-chronic hepatitis B liver failure, GSTP1 methylation showed significantly better predictive value than MELD score [area under the receiver operating characteristic curve (AUC) 0.89 vs. 0.72, P < 0.01; AUC 0.83 vs. 0.70, P < 0.05 respectively]. Meanwhile, patients with GSTP1 methylation levels above the cut-off points showed significantly poorer survival than those below (P < 0.05).
CONCLUSIONS: Aberrant GSTP1 promoter methylation exists in acute-on-chronic hepatitis B liver failure and shows high predictive value for short-term mortality. It might serve as a potential prognostic marker for acute-on-chronic hepatitis B liver failure.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26040771     DOI: 10.1111/apt.13271

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  5 in total

1.  Circulating Receptor-Interacting Protein Kinase 3 Are Increased in HBV Patients With Acute-on-Chronic Liver Failure and Are Associated With Clinical Outcome.

Authors:  Liwen Chen; Zhujun Cao; Lei Yan; Yezhou Ding; Xinghua Shen; Kehui Liu; Xiaogang Xiang; Qing Xie; Chuanwu Zhu; Shisan Bao; Hui Wang
Journal:  Front Physiol       Date:  2020-06-16       Impact factor: 4.566

2.  Aberrant GSTP1 promoter methylation predicts poor prognosis of acute-on-chronic hepatitis B pre-liver failure.

Authors:  Chen-Yang Qiao; Feng Li; Yue Teng; Jing Zhao; Na Hu; Yu-Chen Fan; Kai Wang
Journal:  Clin Exp Med       Date:  2017-07-04       Impact factor: 3.984

3.  IL-6 Promoter Hypomethylation Acts As a Diagnostic Biomarker in Hepatitis B Virus-Associated Hepatocellular Carcinoma.

Authors:  Jie-Ru Yang; Ju Wang; Hai-Ming Li; Shuai Gao; Yu-Chen Fan; Kai Wang
Journal:  Front Oncol       Date:  2022-03-11       Impact factor: 6.244

Review 4.  Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis.

Authors:  Alexander V Ivanov; Vladimir T Valuev-Elliston; Daria A Tyurina; Olga N Ivanova; Sergey N Kochetkov; Birke Bartosch; Maria G Isaguliants
Journal:  Oncotarget       Date:  2017-01-17

5.  Combined use of murine double minute-2 promoter methylation and serum AFP improves diagnostic efficiency in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Jing-Wen Wang; Yu Qian; Chen-Si Wu; Ning-Hui Zhao; Yu Fang; Xiao-Dong Yuan; Shuai Gao; Yu-Chen Fan; Kai Wang
Journal:  Int J Med Sci       Date:  2020-10-23       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.